MiCAN Technologies

MiCAN Technologies has technologies and licenses to produce high function human myeloid lineage cells (Mylc) from human iPS cells. The development and the feasibility studies to launch the cMylc has been conducted with a collaboration to the Research Institute for Microbial Diseases at Osaka University.

MiCAN

ビジネス情報

会社名

MiCAN Technologies

設立

2016

位置

Kyoto, JP

からのスピンアウト

Independent

その他の場所

Kobe, JP

テクノロジーの検証

TRL

7

特許の価値

No data

ビジネスステージ

Spinout / Seed fund stage

ターゲット出口

IPO in other country

次の投資要件

ビジネスパートナーへのメッセージ

MiCAN is looking for global R&D partners to evaluate our iPS derived dendric myeloid cells in the applications of dengue virus and COVID-19 (SARS-CoV-2) research. Also looking for global supply chain partners (distributors) to handle our ready-to-use kit accessible to the global scientists.